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Background: Previous studies have suggested plasma tissue inhibitor of metalloproteinases-
1 (TIMP-1) as a stage independent prognostic marker in colorectal cancer (CRC) patients.
The aim was to validate plasma TIMP-1 and serum carcino-embryonic antigen (CEA) levels
as prognostic indicators in an independent population-based cohort of patients with CRC.
Patients and methods: During 2000–2003, plasma and serum were collected preoperatively
from 322 patients treated for primary CRC. TIMP-1 and CEA levels were determined by val-
idated ELISA platforms.
Results: High TIMP-1 and CEA levels each associated with poor overall survival (OS); TIMP-1
(hazard ratio (HR) 2.1; 95% confidence interval (CI) 1.6–2.7) and CEA (HR 1.2; 95% CI 1.1–1.3),
and disease-free survival (DFS); TIMP-1 (HR 2.0; 95% CI: 1.5–2.6) and CEA (HR 1.2; 95% CI: 1.1–
1.4) in univariate analyses. In stratified analyses of stages II and III, TIMP-1 levels associated
significantly with OS and DFS in stages II and III, associations were not found for CEA. Mul-
tivariate analysis for OS, including TIMP-1 and CEA levels and clinico-pathological baseline
variables, revealed significant association of TIMP-1 (HR 1.8; 95% CI 1.3–2.4) but not CEA lev-
els.
Conclusions: This independent prospective validation study confirms the significant associ-
ation between preoperative plasma TIMP-1 levels and survival of CRC patients: TIMP-1 pro-
vided stronger prognostic information than CEA. Thus, this study brings plasma TIMP-1 to
the next level of evidence for its clinical use as a prognostic marker in CRC patients.
 2010 Elsevier Ltd. All rights reserved.1. Introduction developed countries.1 Although survival has improved, al-Colorectal cancer (CRC) is the most common cancer in Europe
and ranks second as the cause of cancer-related deaths iner Ltd. All rights reserved
fax: +46 21175860.
u.se (H. Birgisson).most half of the patients with CRC are expected to die from
their disease. About one-fifth of patients have non-curable
metastatic disease at diagnosis and for those with curable.
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death, despite the most modern surgical and oncological
treatments.
Major expectations are laid on biomarkers for providing
more precise prognostic information than the current tu-
mour, lymph node and metastasis (TNM) staging system. Car-
cino-embryonic antigen (CEA), which has been studied as a
marker of CRC since the 1960s, is the only soluble biomarker
recommended for use in CRC, being recommended primarily
for monitoring after primary surgery.2 As yet, no serological
biomarkers have obtained sufficient evidence for routine clin-
ical use in identifying poor prognosis stage II CRC patients,
who might be candidates for adjuvant treatment, or good
prognosis stage III patients, who could be saved from adju-
vant chemotherapy or receive a more mild form for adjuvant
treatment other than the oxaliplatin-based treatment gener-
ally used for stage III disease. The latest European Group on
Tumour Markers (EGTM) recommendations failed to identify
additional biomarkers for separating stage II CRC patients
into different prognostic groups.3 However, the EGTM pro-
poses tissue inhibitor of metalloproteinases-1 (TIMP-1) as a
promising new prognostic biomarker, although TIMP-1 needs
to be validated before any conclusion on its use can be drawn.
TIMP-1 regulates the activity of matrix metalloproteinases
(MMP), which are enzymes involved in degradation of the
extracellular matrix (ECM), and thus, may be involved in can-
cer invasion and metastasis.4 CRC patients have higher levels
of plasma TIMP-1 than healthy controls,5–7 whereas, patients
with premalignant adenomas have similar plasma TIMP-1 lev-
els as those of the healthy people.8 Furthermore, high preoper-
ative plasma TIMP-1 levels are associated with poor prognosis
in CRC, independent of stage,9,10 an observation also seen for
high postoperative levels of TIMP-1.11 If plasma TIMP-1 can be
used to reliably identify stage II and stage III CRC patients in
whom adjuvant treatment is indicated and whether it should
be single-drug 5FU or an oxaliplatin-based combination, it
may have high potential for guiding individualised treatment
of these patient groups. However, the use of plasma TIMP-1
as a prognostic parameter in CRC requires that the previous
results be validated independently with patients and patient
samples external to the original institutions. In this context,
there are research groups that have already confirmed the
association of high plasma TIMP-1 levels with poor prognosis
in CRC.12–14 In a medical society where TNM staging of CRC pa-
tients has improved with the help of CT and MRI scans and
where better surgical and oncological treatments are offered,
together with improved pathological examination, it is neces-
sary to continue evaluation of promising biomarkers such as
TIMP-1 on a current CRC cohort.
Therefore, the aim was to validate the plasma TIMP-1 and
the serum CEA levels as prognostic indicators in a population-
based cohort of patients with CRC.
2. Patients and methods
2.1. Patients
The study was prospective and the cohort was population
based, including patients treated for CRC at the Department
of Surgery, Central District Hospital, Va¨stera˚s, County of Va¨st-manland, Sweden, which has 260,000 inhabitants in the re-
gion. The study period was between August 2000 and
December 2003 and the inclusion criterion was histologically
verified adenocarcinoma of the rectum or colon. Acceptance
to participate and to provide blood samples for tumour mar-
ker studies was by informed consent.
Information on tumour stage, microscopic resection mar-
gins, grade of differentiation and vascular and neural inva-
sion was retrieved from pathology reports.
In the Regional Oncology Registry, 415 patients were trea-
ted for CRC in the county of Va¨stmanland during this period.
From these patients, 322 patients (stages I–IV) were included
in the study, of which 271 had curative resections. The main
reasons for non-inclusion (n = 93) were acute operation
(n = 32), patients who were not able or did not want to partic-
ipate in the study (n = 19), non-admission to the hospital be-
cause of palliative care (n = 8), cancer in a polyp (n = 7) and
for 27 patients the reason for non-inclusion was unknown.
Information on cancer recurrence, death and cause of death
of the study cohort was sampled by matching with the Regio-
nal Oncology Registry and hospital records.
2.2. Blood sampling
The day before the planned resection of the CRC, blood sam-
ples were drawn preoperatively into endotoxin-free collection
tubes with EDTA as an anticoagulation agent for plasma.
Tubes without anticoagulation agent were used for serum.
The blood samples were processed for plasma and serum by
centrifugation at 2000g for 10 min at room temperature. The
samples were stored at )70 C until analysed for TIMP-1 and
CEA in 2008.
2.3. Timp-1
All assays were performed without knowledge of the clinico-
pathological data. A thoroughly validated ELISA was used to
measure TIMP-1 levels in plasma.15 In brief, an affinity-purified
sheep polyclonal anti-TIMP-1 antibody was used to capture
TIMP-1 in the specimens. MAC15, a murine monoclonal anti-
TIMP-1 IgG1, was used to detect the TIMP-1: the MAC15 anti-
body recognises both free and MMP-bound TIMP-1, therefore,
the assay can be considered as a total TIMP-1 assay. A rabbit
anti-mouse immunoglobin/alkaline phosphatase conjugate
(No. D0314, DAKO, Glostrup, Denmark) was used for kinetic rate
measurements, which were collected every 10 min over a 1 h
period. KinetiCalc II software (Bio-Tek Instruments, Winooski,
VT) was used to calculate the TIMP-1 levels in the specimens.
Before performing the assay, all specimens were thawed at
37 C. On each plate, four reference plasma samples were in-
cluded to ensure optimal performance of the assay on each as-
say run. The intra- and inter-assay variations were below 10%.
2.4. CEA
The CEA determination was on serum with a commercially
available MTPL-EIA kit (RE59101) (IBL; Immuno Biological Lab-
oratories; http://www.ibl-hamburg.com). The analysis is
based on the principle of a Solid-Phase-Enzyme-Linked
immunosorbent assay. According to the manufacturer’s
Table 1 – The characteristics of the cohort including 322
patients with colorectal cancer and the data are presented as
numbers.
Variable Label n
Gender Male 163
Female 159
Localisation Colon 216
Rectum 106
Disease stage I 44
II 134
III 94
IV 46
Unknown 4
Differentiation grade Well-moderate 249
Poor 70
Unknown 3
Vascular invasion Present 38
Not present 276
Unknown 8
Neural invasion Present 8
Not present 306
Unknown 8
Mucinous Present 43
Not present 271
Unknown 8
Number of lymph nodes analysed <12 95
P12 224
Unknown 3
E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 3 3 2 3 –3 3 3 1 3325instructions, this assay has a detection limit of 1 ng/ml and
the standard range is 5–75 ng/ml.
2.5. Endpoints
Endpoints were defined according to the recommendations of
Punt and colleagues.16 Overall survival (OS) was measured
from the date of surgery to the date of death from all causes.
Cancer-specific survival (CSS) was measured from the date of
surgery to the date of death by CRC; the observations were
censored at death from causes other than CRC and at the
end of the study period. Curatively resected patients were de-
fined as all patients included with stages I–III disease and
microscopically free resection margins (R0). For the curatively
resected patients, disease-free survival (DFS) was calculated
and measured from the date of surgery to the date of diagno-
sis of a local/distal recurrence, second primary CRC/non-CRC,
or the date of death due to cancer. Time to recurrence (TTR)
was calculated and measured from the date of surgery to
the date of diagnosis of a local/distant recurrence or to the
date of death due to CRC and censored at the date of death
due to reasons other than CRC. A second primary CRC/non-
CRC was not regarded as recurrence. All observations were
censored at the end of the study period (15th November
2008). The recommendations by REMARK17 were followed.
2.6. Statistical methodology
Descriptive statistics are presented by frequencies and per-
centages for categorical data and by the median and range
(quartiles as well) for continuous variables. Spearman rank
correlation coefficient was used as a measure of association
and tests for location were with the Wilcoxon rank sum test.
The Kaplan–Meier method was used to estimate survival prob-
abilities, and the log-rank test was used to test for equality be-
tween strata grouping TIMP-1 and CEA by their respective
tertiles for graphical presentation. The Cox proportional haz-
ards model was applied for univariate analyses and for multi-
variate analyses of OS and DFS. The levels of TIMP-1 and CEA
were log transformed (log2 this means a twofold difference in
the marker level corresponded to the estimated hazard ratio
(HR)) and treated as continuous variables for the uni- and mul-
tivariable analyses of OS and DFS. The assumption of the pro-
portional hazards model and the linearity were validated
graphically and by examination of the residuals. The signifi-
cance level was set to 5%. The SAS software package (version
9.1; SAS Institute, Cary, NC, USA) was used to manage patient
data and to perform all statistical analyses.
Note: The resulting multivariate estimates could be used to
define clinically relevant cutpoints: these would be adjusted
for age, gender and other potential confounders.
Ethical approval (no. 00-001) was obtained from the Ethics
Committee at Uppsala University, Uppsala, Sweden.
3. Results
3.1. Patient characteristics
The total number of patients included in the study was 322
and the median observation time for surviving patients was6.5 years (range 4.9–8.2 years). Major clinico-pathological
characteristics and marker levels of the cohort are presented
in Table 1. The median age was 73 years (range 34–94 years)
and the median number of lymph nodes analysed were 15
(range 1–55). Two older patients with rectal cancer and one
with colon cancer in a polyp had a local excision of the tu-
mour and one patient with locally advanced colon cancer
was treated with radio-chemotherapy only; therefore, these
patients did not have a definitive disease stage (Table 1). Six
patients with colon cancer and none with rectal cancer
underwent acute resection. Among the 322 included patients,
271 patients had curative resection. Preoperative radiation
therapy was used in 79 rectal cancer patients, three received
chemoradiation therapy and one (stage IV) neoadjuvant che-
motherapy only. One patient with distal sigmoid colonic can-
cer received preoperative radiation therapy and one colonic
cancer received neoadjuvant chemotherapy. Adjuvant che-
motherapy was given in 71 colon and 34 rectal cancer pa-
tients, mainly to those under 75 years with stage III disease.
Fifty-five curatively resected patients developed cancer
recurrence (20%), one patient had local recurrence and distant
metastasis, two had local recurrence only, and 52 had distant
metastases only. For the curatively resected patients, one
recurrence was observed in two patients treated with only lo-
cal excision, one (2%) in the 44 patients with stage I, 17 (13%)
in the 133 patients stage II patients and 36 (39%) in the 92 pa-
tients with stage III.
3326 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 3 3 2 3 –3 3 3 13.2. Tumour marker levels
CEA levels correlated with disease stage (P < 0.01) and cura-
tive resection (P < 0.01), and marginally with vascular inva-
sion (P = 0.04), with higher levels seen in advanced disease
stages, non-curatively treated patients and in patients where
vascular invasion was seen in the tumour. No significant
associations were found for localisation, differentiation grade
and neural invasion. TIMP-1 associated marginally with cura-
tive resection (P = 0.05), but not with any of the other clinico-
pathological variables. Increased age correlated with high
TIMP-1 levels (P < 0.01) in Spearman rank correlation: an
association that was not seen for CEA levels (P = 0.22). Gender
was not associated with TIMP-1 or CEA levels or age. For the
whole cohort, the median TIMP-1 level was 156 ng/ml (range
57–613) and the median CEA level was 2.7 ng/ml (range 0–
2000).
TIMP-1 and CEA levels were interrelated with high levels of
TIMP-1 seen in patients with high levels of CEA, also seen in
each subgroup of disease stage.
3.3. Survival analysis
The number of events was 147 (46%) for OS, 80 (25%) for CSS,
125 (46%) for DFS and 55 (20%) for TTR. In the total population
(n = 322), high TIMP-1 and CEA levels treated as continuous
variables were associated with poorer OS, CSS and DFS in uni-
variate COX model analyses, with TIMP-1 levels more signifi-
cantly associated than CEA (Table 2). Increased CEA levels
associated marginally with shorter TTR, a correlation not
shown for TIMP-1.
Tertiles were used to divide TIMP-1 and CEA levels in the
Kaplan–Meier estimates of survival probabilities and the
log-rank test was used for comparing strata. These plots are
primarily graphical illustrations and the cutpoints should
not be interpreted otherwise. Increased TIMP-1 and CEA lev-
els revealed significant association with poor OS (Fig. 1a and
b). Stratifying the data into disease stages II and III revealed
a significant association of increased TIMP-1 levels with
poorer OS in patients with CRC stages II (P = 0.02) and III
(P < 0.01) (Fig. 1c and d): a correlation that could not be shown
for CEA (P = 0.1 and P = 0.13) (Fig. 1e and f).
A similar analysis with DFS as endpoint revealed signifi-
cant association of high TIMP-1 levels with poor DFS
(P < 0.01) (Fig. 2a). These correlations were also significant in
stratified analyses of stage II (P < 0.01) (Fig. 2b; Table 3) andTable 2 – Association of TIMP-1 and CEA levels in patients with
model analyses.
Endpoint n TIMP-1
HR 95% CI
OS 322 2.1 1.6–2.7
CSS 322 1.9 1.3–2.6
DFS 271 2.0 1.5–2.6
TTR 271 1.4 0.95–2.1
TIMP-1: tissue inhibitor of metalloproteinases 1; CEA: carcino-embryon
disease-free survival; TTR: time to recurrence; HR: hazard ratio; and CI:stage III (P < 0.01) (Fig. 2c; Table 3). CEA levels were not signif-
icantly correlated with DFS in these analyses (Table 3).
Multivariate Cox regression analysis for OS, including the
TIMP-1 and CEA levels and clinico-pathological baseline vari-
ables, for all 322 patients revealed significant association of
TIMP-1 (P < 0.01) but not CEA (P = 0.20) (Table 4). Other signif-
icant variables were age, disease stage, and postoperative
chemotherapy.
The same multivariate model was used for the curatively
resected patients (n = 271). This analysis revealed the same
individual relationship of high TIMP-1 with poor OS (HR 1.9;
95% CI 1.4–2.7), with age and disease stage as other individual
significant parameters.
3.4. Time to recurrence
Stage III patients were stratified into four groups based on age
and gender; adjusted CEA and TIMP-1 levels; and, whether
adjuvant chemotherapy was given, or not. The analysis re-
vealed significant differences in TTR, with those having high
TIMP-1 and/or CEA and not receiving adjuvant treatment hav-
ing the highest risk for recurrence, and those with low TIMP-1
and/or low CEA and treated with adjuvant chemotherapy
having the lowest risk for recurrence (Fig. 3). However, these
interactions were not significant (P = 0.20) during multivariate
analysis including lymph node (N) stage (N1 versus N2).
4. Discussion
This prospective study confirmed the significant associations
between high preoperative plasma TIMP-1 levels and poor
survival of patients with primary CRC. These associations
were observed for both DFS and OS analyses of the entire co-
hort, in the stratified analyses of stages II and III disease and
in the multivariate analyses including conventional clinico-
pathological baseline parameters.
Thus, this study can be considered as an independent pro-
spective validation study that confirmed our previous results
on TIMP-1 in the prognostic setting of CRC, i.e. previous re-
sults have consistently ascertained9–11,18 that increased plas-
ma TIMP-1 levels are significantly associated with poor
prognosis:, this is also supported by other groups.12–14
The basis of present prognostic estimation and prediction
of recurrence in patients with CRC is the TNM staging sys-
tem.19 Curative treatment of CRC can only be achieved with
a resection of the primary tumour and eventual metastases.colorectal cancer with different endpoints, univariate COX
CEA
P-value HR 95% CI P-value
<0.01 1.2 1.1–1.30 <0.01
<0.01 1.3 1.2–1.4 <0.01
<0.01 1.2 1.1–1.4 <0.01
0.09 1.2 1.1–1.3 0.03
ic antigen; OS: overall survival; CSS: cancer specific survival; DFS:
confidence interval.
Fig. 1 – Kaplan–Meier estimates of overall survival stratified by TIMP-1 and CEA levels with the respective tertiles as cutpoints.
(a) TIMP-1 all patients; (b) CEA all patients; (c) TIMP-1 stage II; (d) TIMP-1 stage III; (e) CEA stage II; AND (f) CEA stage III. The
number of patients at risk at 0, 12, 24, 36, 48 and 60 months are shown below the axis and the number of events (deaths) to
the left. P-values are for the log-rank statistic. TIMP-1: tissue inhibitor of metalloproteinase 1; CEA: carcino-embryonic
antigen and OS: overall survival.
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alone, preoperative radiation or radio-chemotherapy in case
of rectal cancer, adjuvant single-drug or combination chemo-
therapy in colon cancer or palliative chemotherapy in ad-
vanced cancers. The aim of modern cancer treatment is to
individualise therapy through the identification of patientswith high recurrence risks and offer the patients neoadjuvant
or more intense adjuvant therapy, while omitting these treat-
ments in patients with low risk of recurrence. Such proce-
dures would improve patient survival and quality of life by
reducing the probability of adverse effects and optimise the
use of health care resources.
Fig. 2 – Kaplan–Meier estimates of disease-free survival in curatively treated patients with colorectal cancer, stratified by
TIMP-1 levels with the tertiles as cutpoints. (a) All curatively treated patients; (b) disease stage II and (c) disease stage III. P-
value is for the log-rank statistic. The number of patients at risk at 0, 12, 24, 36, 48 and 60 months are shown below the axis
and the number of events to the left. TIMP-1: tissue inhibitor of metalloproteinase 1; CEA: carcino-embryonic antigen and
DFS: disease-free survival.
Table 3 – Univarate Cox regression analyses for OS and DFS for TIMP-1, and CEA stratified for patients with disease stages II
and III colorectal cancer.
Endpoint n TIMP-1 CEA
HR 95% CI P-value HR 95% CI P-value
OS stage II 134 2.3 1.5–3.7 <0.01 1.1 0.97–1.4 0.11
DFS stage II 133 2.1 1.3–3.5 <0.01 1.1 0.96–1.4 0.15
OS stage III 94 2.8 1.8–4.4 <0.01 1.1 0.98–1.3 0.10
DFS stage III 92 2.3 1.0–4.9 0.04 1.1 0.83–1.3 0.66
TIMP-1: tissue inhibitor of metalloproteinases 1; CEA: carcino-embryonic antigen; OS: overall survival; DFS: disease-free survival; HR: hazard
ratio; and CI: confidence interval.
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serological biomarker in CRC,2 with a well-documented corre-
lation with recurrence and survival.20–22 CEA is used to subdi-
vide stage II patients into prognostic groups of high- and
low-risk patients,23 and is included in advanced nomograms
for improving prognostic stratification of CRC patients.24 How-
ever, CEA is unspecific and the sensitivity is considered insuf-
ficient for this purpose.25 Thus, there is still a need for
additional biomarkers to be included in the daily management
of patients with CRC. Some of the markers under evaluationinclude soluble uPAR variant forms,26 YKL-4027 and miRNA.28
In addition, tissue markers, such as KRAS mutations and the
presence of microsatellite instability, may be included in
the near future as predictors of response to a particular
treatment.
Plasma TIMP-1 has been suggested by EGTM as a promis-
ing prognostic biomarker. TIMP (1, 2, 3 and 4) regulate the
activity of MMP,4 enzymes involved in degradation of ECM
and in cancer invasion and metastasis. Other specific
functions of TIMP-1 are regulation of cell proliferation,29
Table 4 – Multivariate Cox regression analysis of all CRC patients (stages I–IV) for OS including the TIMP-1 and CEA levels and
clinicopathological baseline variables.
Parameter Pr > v2 Hazard ratio 95% Hazard ratio confidence limits
Analysis of maximum likelihood estimates
TIMP-1 (log base 2) <0.01 1.8 1.3 2.4
Age (pr 10 year difference) <0.01 1.4 1.1 1.7
Disease stage I versus IV <0.01 0.06 0.03 0.14
Disease stage II versus IV <0.01 0.06 0.03 0.12
Disease stage III versus IV <0.01 0.19 0.11 0.31
Postoperative chemotherapy yes/no 0.05 0.59 0.35 1.0
Removed
Localisation 0.98
Vascular invasion 0.88
Gender 0.22
Preoperative radiation therapy 0.21
CEA 0.20
Tumour differentiation grade 0.12
TIMP-1: tissue inhibitor of metalloproteinases 1; CEA: carcino-embryonic antigen; OS: overall survival; and CRC: colorectal cancer.
Fig. 3 – Kaplan–Meier estimates of time to recurrence in
curatively treated stage III patients, stratified into four
groups based on age- and gender-adjusted CEA and TIMP-1
levels, and whether adjuvant chemotherapy was given or
not. Group 1: low TIMP-1 and without adjuvant chemo-
therapy; Group 2: high TIMP-1 level and without adjuvant
chemotherapy; Group 3: low TIMP-1 level and with adjuvant
chemotherapy and Group 4: high TIMP-1 level and with
adjuvant chemotherapy. P-value is for the log-rank statistic.
The number of patients at risk at 0, 12, 24, 36, 48 and
60 months are shown below the axis and the number of
events to the left. TIMP-1: tissue inhibitor of metallopro-
teinase 1; CEA: carcino-embryonic antigen and TTR: time to
recurrence.
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not expressed by the cancer cells but are synthesised and se-
creted by adjacent stromal fibroblasts.32
Theoretically, TIMP-1 over-expression should inhibit tu-
mour cell invasion and metastasis due to inhibition of MMP.
Paradoxically, increased TIMP-1 expression is associated with
negative prognosis in solid tumours.13,33 The increased
expression of TIMP-1 may be related to the increased expres-sion of MMP during tumour progression; therefore, elevated
levels of TIMP-1 in patients with invasive carcinomas may
represent one of the host’s responses to the remodelling stim-
uli through balancing local tissue degradation.4 It should be
noted, however, that we have not been able to demonstrate
a clear association between MMP and TIMP-1 expression lev-
els in colorectal cancer.34 Increased TIMP-1 levels may in
addition to MMP inhibition prevent apoptosis, thereby,
improving cancer cell survival. It may also induce hepatocyte
growth factor, which aids in the development of liver metas-
tases.35 CRC is primarily diagnosed in the elderly population,
although the range of ages at diagnosis is wide. Age together
with disease stage is the strongest individual predictor of OS
in CRC patients, but does not appear to influence the risk of
recurrence. However, there are indirect effects of age: young
patients have more advanced disease stage36 and older pa-
tients are less likely to be treated with adjuvant chemother-
apy.37 This was reflected in the present cohort, where no
patients 76 years or older and with stage III disease received
chemotherapy (data not presented). However, there is a
non-documented trend in Sweden since the 1990s that older
patients receive chemotherapy based on estimation of bio-
logic age and lack of co-morbidities.38
Age is particularly important in survival analysis for TIMP-
1, as TIMP-1 levels increase with age and this can directly
influence association with OS and DFS, and indirectly CSS
and TTR, as older patients often do not obtain adjuvant treat-
ment. Therefore, the analyses were corrected for age as a con-
founder by stratified and multivariate analyses: CEA had no
association with age.
The difference in TTR in stage III patients stratified accord-
ing to age- and gender-adjusted TIMP-1 and CEA levels and
postoperative chemotherapy revealed major differences in
recurrences, with only 17% developing recurrences in the
group with low TIMP-1 and receiving adjuvant treatment,
compared to 58% in the group with high TIMP-1 and no adju-
vant treatment. Patients with both high and low values of
TIMP-1 appeared to respond to postoperative chemotherapy
(mainly 5FU and oxaliplatin in this cohort, data not shown).
Although adjusted for age, the present cohort may be
3330 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 3 3 2 3 –3 3 3 1confounded through only younger patients (<75 years) being
offered adjuvant treatment.
TIMP-1 might be used as a prognostic marker identifying
patients with poor prognosis and then offering these high
TIMP-1 patients additional treatment. An example of this is
seen in the stage III patients in this cohort (Fig. 3) where pa-
tients with high TIMP-1 levels receiving no chemotherapy
have the highest risk of recurrence. Of specific interest is that
stage III-high TIMP-1 patients appear to receive benefit from
adjuvant chemotherapy, i.e. high TIMP-1 patients seem to
be responsive to adjuvant chemotherapy. However, it should
be kept in mind that the results may be confounded by the
fact that older individuals have higher TIMP-1 and are less
likely to receive chemotherapy at the time of the study.
In conclusion, this independent prospective validation
study confirms the significant association between preopera-
tive plasma TIMP-1 levels and survival of CRC patients: TIMP-
1 provided stronger prognostic information than CEA. Thus,
this validation study confirms initial observations on plasma
TIMP-1 as a stage independent prognostic marker for CRC pa-
tients and thus brings plasma TIMP-1 to Level of Evidence II,
according to the Tumour Marker Utility Grading System for
tumour marker evaluation described by Hayes and
colleagues.39
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